SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Akorn Inc. -- Ignore unavailable to you. Want to Upgrade?


To: par284 who wrote (87)3/21/2000 2:04:00 PM
From: Czechsinthemail  Read Replies (1) | Respond to of 101
 
Akorn, Inc (AKRN) Dain Rauscher Wessels initiates coverage of developer of diagnostic and therapeutic specialty pharmaceuticals, with a STRONG BUY and price target of $20. We are particularly intrigued by the company's R&D pipeline, which targets conditions that are inadequately addressed by today's healthcare system, such as age-related macular degeneration.